Replies to post #800632 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

I do not see how AFTER MAA, you can "believe with every fiber of my being that this technology saves lives and has incredible potential value" and yet conclude "which takes us into 2027 with no massive spike and constant dilution." These two truths are incongruent and will not both happen. Pick one or the other, both do not make sense after MAA

Both can unfortunately be true at the same time. Scientists and doctors like Dr. Liau can create potential to save lives but then corporate executives like those at NWBO and of course bureaucrats like those at NICE and FDA (who come into play after a decision by MHRA) have to convert that potential into reality.

So saving large handfuls of lives now and having the potential to save many more does not mean that even with MHRA approval that this management team will be skillful enough to turn that potential into profit for the shareholders who bankrolled all this by averaging down and taking hit after punishing hit of dilution.

[10baggerz]

I have always appreciated your positivity and enthusiasm. I respectfully disagree (although I'd be happy to be wrong) that MAA approval alone will somehow magically free us from the shackles of mm's/shorts.
It seems to me that NICE reimbursement will be conditional on Flaskworks approval/integration, otherwise WHY HAVEN'T THEY SUBMITTED ANYTHING TO NICE YET? 
So between the continued lack of meaningful revenues, the cost of manufacturing buildout/approval. the TIME it will take to gain NICE reimbursement, and the the continued need to dilute to finance everything (THAT'S WHY THEY NEED 900 MILLION MORE SHARES), I just don't see how the company will be able to protect any approval spike.
So unless they have a PARTNERSHIP announcement to go along with approval, where is the sustainable share price growth going to come from?
Again, nothing would make me happier than to be completely wrong.